915941-95-6

Basic information

• Product Name: N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide
• Synonyms: N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide;N-[4-[3-chloro-4-(2-pyridylMethoxy)anilino]-3-cyano-7-ethoxy-6-quinolyl]acetaMide;Acetamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-;4-[3-Chloro-4-[(2-pyridyl)methoxy]anilino]-3-cyano-7-ethoxy-6-(N-acetylamino)quinoline;N-(4-{[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino}-3-cyano-7-eth oxy-6-quinolinyl)acetamide;N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]acetamide
• CAS NO: 915941-95-6
• Molecular Formula: C26H22ClN5O3
• Molecular Weight: 487.93758
• Mol File: 915941-95-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 699.9°C at 760 mmHg
• Flash Point: 377.1°C
• Appearance: /
• Density: 1.38g/cm³
• Vapor Pressure: 1.95E-19mmHg at 25°C
• Refractive Index: 1.676
• PKA: 14.03±0.43(Predicted)
• CAS DataBase Reference: N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide(915941-95-6)
• EPA Substance Registry System: N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide(915941-95-6)

Safety Data

• Hazardous Substances Data: 915941-95-6(Hazardous Substances Data)

Usage

General Description

N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide is a complex chemical compound with a long and specific name. It is a synthetic organic compound that belongs to the class of quinolines and amides. It contains various functional groups including amino, cyano, and ethoxy groups, as well as chloro and pyridinyl substituents. N-(4-((3-Chloro-4-(pyridin-2-ylMethoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)acetaMide may have potential pharmacological or biological activity due to its structural features, and it could be used as a starting material for the development of new drugs or as a research tool in the field of medicinal chemistry. Its precise properties and biological effects would need to be determined through further study and testing.

InChI:InChI=1/C26H22ClN5O3/c1-3-34-25-12-22-20(11-23(25)31-16(2)33)26(17(13-28)14-30-22)32-18-7-8-24(21(27)10-18)35-15-19-6-4-5-9-29-19/h4-12,14H,3,15H2,1-2H3,(H,30,32)(H,31,33)

Upstream product

• 4377-33-7 2-chloromethylpyridine 
• 848133-75-5 3-cyano-4-hydroxyl-6-acetamido-7-ethoxyquinoline 
• 179687-79-7 2-((2-chloro-4-nitrophenoxy)methyl)pyridine 
• 619-08-9 2-chloro-4-nitrophenol 
• 848133-74-4 3-(4-acetamido-3-ethoxyaniline)-2-cyanopropenoic acid ethyl ester 
• 848655-78-7 4-acetamido-3-ethoxyaniline 
• 121-88-0 5-Nitro-2-aminophenol 
• 6959-47-3 2-chloromethylpyridine hydrochloride 
• 116496-76-5 4-acetamido-3-ethoxynitrobenzene 
• 25351-89-7 N-(2-hydroxy-4-nitrophenyl)acetamide 
• 3964-52-1 2-chloro 4-aminophenol 
• 1201080-09-2 N-(3-cyano-7-ethoxy-4-oxo-1,4-dihydroquinolin-6-yl)acetamide 
• 524955-09-7 3-chloro-4-(2-pyridylmethoxy)aniline 
• 848133-76-6 7-ethoxy-6-acetylamino-4-chloro-quinoline-3-carbonitrile 

Relevant articles and documents

Neratinib intermediate crystal as well as preparation method and application thereof

The invention relates to a neratinib intermediate crystal as well as a preparation method and application thereof. The invention especially relates to a crystal form II of an intermediate A compound 6-amino-4-(3-chloro-4-(pyridine-2-substituted methoxy) aniline)-7-ethoxyquinoline carbonitrile. The crystal form II comprises diffraction peaks with diffraction angles 2 theta of 6.3 degrees, 7.8 degrees, 14.0 degrees, 15.1 degrees, 17.1 degrees, 18.8 degrees, 21.5 degrees, 22.2 degrees, 23.4 degrees and 27.5 degrees in an XRPD spectrum. When the intermediate crystal form II is used for preparing the neratinib, the dosage of a solvent can be remarkably reduced, the reaction time is shortened, the yield is increased, and meanwhile, the residual quantity of the intermediate A in a final product is remarkably reduced.

Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro

The discovery and development of a novel HER-2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer are presented in this article. EGFR family has been recognized as a crucial meditator in the cancer progression; HER-2 tyrosine kinase was one of the members among them. In the effort to explore potent HER-2 inhibitors, a novel series of 4-anilino-3-cyanoquinoline derivatives have been designed, synthesized and evaluated. Most compounds possessed modest proliferation inhibition on SK-BR-3 cell line and HER-2 kinase. Compound 16 appeared to be the most potent compound (HER-2 kinase IC50: 19.4?nM, SK-BR-3 IC50: 94?nM). In the experiment of cellular cytotoxicity assay, compound 16 shows a much lower cytotoxicity than neratinib on Beas-2b cell line (Human bronchial epithelial cells). In conclusion, compound 16 would be a promising lead compound for further anti-breast cancer drug discovery.

COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1

Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.